Clearly it is a positive. It should set the stage for the deal to be closed in September.
I'm not saying Abbott is going to buy them tomorrow, but I think it's the first friendly overture that could lead to a long relationship.
I've been a little perplexed. I've always felt that Boston Scientific offers have been superior. I've not understood the loyalty of Guidant's board to J&J.
Six months ago, people believed there was good chance he (Tobin) would leave.
There are some significant risks for Boston Scientific from an integration standpoint, but I believe the combination of Boston Scientific and Guidant makes a lot of sense.
They have really alleviated the issues about an antitrust review.
They missed the (forecast) by $1 million, and it's a very choppy tape for small medical device companies.
Underneath the covers I believe that Abbott wants to be a device player and for the first time they are making a real legitimate stand to become one. If Boston doesn't get Guidant, at this valuation, I think Abbott ultimately buys Boston.
We were extremely impressed by the solid results posted in the first quarter and would be buyers of the stock at current levels.
We're supporting it because it's a huge opportunity.
This website focuses on proverbs in the Swedish, Danish and Norwegian languages, and some parts including the links below have not been translated to English. They are mainly FAQs, various information and webpages for improving the collection.
This website focuses on proverbs in the Swedish, Danish and Norwegian languages, and some parts including the links below have not been translated to English. They are mainly FAQs, various information and webpages for improving the collection.